Articles & Announcements
Stay current on the latest from Tolmar.
We keep ourselves at the forefront of treatment and therapy advancements. Explore our innovative ideas and insights into the world of pharmaceuticals.
Rare Disease Day
Real-World Data Analysis Published in the Journal of Urology Explores Frequency of Late Luteinizing Hormone-Releasing Hormone Agonist (LHRH) Dosing and Impact on Testosterone Suppression in Patients with Prostate Cancer
Data on Nadir Testosterone Levels Achieved by ELIGARD® (leuprolide acetate) for injectable suspension published in Reviews in Urology
Tolmar Pharmaceuticals Champions Prostate Cancer Awareness Month
Data From Tolmar Pharmaceuticals on ELIGARD Demonstrate Serum Leuprolide Levels Required to Maintain Stable, Long-Term Testosterone Suppression Across All Doses Serum Level of Leuprolide Acetate Required to Maintain Low T Established
Tolmar, Inventor and Developer of ELIGARD® (leuprolide acetate for injectable suspension), Announces Plans to Expand Manufacturing Facilities in Colorado
Tolmar Pharmaceuticals Announces That FDA Approval Has Been Received For ELIGARD® (leuprolide acetate for injectable suspension) Storage at Room Temperature For up to 8 Weeks
Data From Tolmar Pharmaceuticals Demonstrate ELIGARD® (leuprolide acetate for injectable suspension) Consistently Suppresses Serum Testosterone Levels in Patients With Advanced Prostate Cancer
Tolmar In the News
We’re proud of the work we do to bring scientific and clinical advancements to the world of pharmaceuticals. Check out the latest on how Tolmar is making a difference in our communities.